TD-1792 is a multivalent glycopeptide-cephalosporin heterodimer antibiotic with potent activity against Gram-positive bacteria. We tested TD-1792 against 377 anaerobes and 34 strains of Corynebacterium species. Against nearly all Gram-positive strains, TD-1792 had an MIC 90 of 0.25 g/ml and was typically 3 to 7 dilutions more active than vancomycin and daptomycin.
I
ncreasing resistance of Gram-positive organisms has necessitated development of new antimicrobial agents with novel mechanisms of activity to counter such strains (8, 12, 15, 21) . TD-1792 is a multivalent bactericidal antibiotic that is chemically a glycopeptide-cephalosporin heterodimer (18) . While its molecular mechanism of inhibition is still under investigation, it was hypothesized that the two component moieties simultaneously target D-Ala-D-Ala-containing peptidoglycan precursors and the active site of penicillin binding proteins (PBPs), resulting in potent bactericidal activity against clinically relevant Gram-positive pathogens, including multidrug-resistant organisms such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycinintermediate S. aureus (VISA) (3, 16) . The antibacterial activity of TD-1792 cannot be reproduced by its individual components tested alone or together as separate molecules; covalent linkage of the glycopeptide and cephalosporin components is required for the potent activity of TD-1792 (2, 9, 10, 14, 22) .
Anaerobic Gram-positive organisms and corynebacteria are frequently part of polymicrobial infections (17, 20) . In moderate to severe diabetic foot infections, a variety of Corynebacterium species were reported to be present in 116 of 454 (25.6%) cases (4) and have been regarded as important pathogens (1) . Many of these organisms exhibit resistance to most categories of antimicrobial agents, and some clostridia and lactobacilli are resistant to glycopeptides (11) . To determine the in vitro activity of TD-1792, we tested 377 anaerobic isolates and 34 Corynebacterium species recovered from clinical infections (1), using the reference agar dilution method.
Of the isolates used in this study, 91% were recovered from polymicrobial clinical specimens, such as intra-abdominal or skin and soft tissue specimens, during 2001 to 2006. The remaining organisms were comprised of previously isolated, less frequently encountered strains, such as Propionibacterium granulosum, P. avidum, Lactobacillus casei, Actinomyces viscosus, and anaerobic Gram-positive cocci, some with previously determined unusual patterns of resistance to clindamycin or fluoroquinolones. Isolates were identified by standard methods (13, 19) and, in some instances, by 16S gene sequencing. The strains were maintained at Ϫ70°C and transferred twice on supplemented Brucella agar (anaerobes) or blood agar (corynebacteria) prior to testing. Quality control strains of Clostridium difficile (ATCC 700057) and Staphylococcus aureus (ATCC 29213), as well as Bacteroides fragilis (ATCC 25285) and B. thetaiotaomicron (ATCC 29741) when testing anaerobic Gram-negative organisms, were included each day of testing.
The comparator antimicrobial agents were vancomycin, daptomycin, linezolid, metronidazole, ampicillin, imipenem, and piperacillin-tazobactam. The powders were obtained from their respective manufacturers or from USP (Rockville, MD) or SigmaAldrich (St. Louis, MO) and were reconstituted according to CLSI guidelines (6) . Daptomycin was tested in media supplemented with Ca 2ϩ to 50 mg/liter. Agar dilution was performed according to standard methods (5, 6) . Serial 2-fold dilutions were added to molten supplemented Brucella agar (anaerobes) or Mueller-Hinton blood agar (corynebacteria) to prepare the plates. The organisms were suspended in broth to achieve turbidity equal to the 0.5 McFarland standard and applied to the drug-containing plates with a Steers replicator that delivered ϳ10 5 CFU/spot for anaerobes and diluted 1:10 for ϳ10 4 CFU/spot for corynebacteria. Drug-free plates were included as growth controls. The anaerobic organisms were incubated at 37°C for 44 to 48 h in an anaerobic chamber and the aerobic organisms incubated at 37°C for 24 to 48 h in ambient air and then examined for growth. The MIC was defined as the concentration of antimicrobial agent that resulted in a marked reduction of growth compared to that on the drug-free control plates.
The MIC results are shown in Table 1 . TD-1792 was the most active antimicrobial agent against the majority of the Gram-positive strains evaluated in this study. The activity of TD-1792 against clostridia was particularly noteworthy. All Clostridium innocuum isolates were susceptible to 0.125 g/ml of TD-1792, while the MIC 90 for both vancomycin and daptomycin was 16 g/ml. Against Clostridium perfringens, the MIC 90 for TD-1792 was 0.03 g/ml, in contrast to 2 g/ml for daptomycin. Based on the MIC 90 , TD-1792 was 16-fold more active (MIC 90 , 0.25 g/ml) than vancomycin (MIC 90 , 4 g/ml) against Clostridium ramosum, all strains of which were also resistant to daptomycin (MIC 90 , Ͼ32 on September 10, 2017 by guest http://aac.asm.org/ g/ml) and linezolid (MIC 90 , Ͼ8 g/ml). However, TD-1792 was less potent against C. difficile (MIC 90 , 1 g/ml), and its activity was similar to those of vancomycin (MIC 90 , 1 g/ml) and daptomycin (MIC 90 , 2 g/ml). All five strains of L. casei tested were resistant to vancomycin (MIC Ͼ 32 g/ml). Four of these had a TD-1792 MIC of 1 g/ml, and one had a TD-1792 MIC of Ͼ8 g/ml. The latter strain of L. casei was also resistant to ampicillin, imipenem, and piperacillintazobactam. The identity of this isolate was confirmed by 16S rRNA gene sequencing.
TD-1792 was equally effective against susceptible and resistant anaerobic Gram-positive cocci; the TD-1792 MIC 90 was 0.03 g/ml for both 48 susceptible strains and 38 strains previously profiled with resistance to clindamycin, tetracycline, erythromycin, or moxifloxacin. One strain of Peptostreptococcus anaerobius (identification confirmed by 16S gene sequencing) had an ampicillin MIC of Ͼ8 g/ml (beta-lactamase negative) and a piperacillin-tazobactam MIC of 16 g/ml but was susceptible to TD-1792 at an MIC of 0.25 g/ml.
Actinomyces and Propionibacterium species were highly susceptible to TD-1792, with MIC 90 s of Յ0.125 g/ml, similar to those for ampicillin, to which these organisms were all susceptible at 0.25 g/ml.
TD-1792 was the most active agent tested against all 34 Corynebacterium species examined in this study, with all organisms, including multidrug-resistant strains, susceptible at Յ0.25 g/ml. Vancomycin, daptomycin, and linezolid were also consistently active against all strains, but the beta-lactams showed variable activity, with resistance noted in C. jeikeium, C. tuberculostearicum, and C. urealyticum.
TD-1792 showed poor activity against most Gram-negative anaerobes, including Bacteroides group species, Prevotella spp., Bilophila wadsworthia, Sutterella wadsworthensis, and Desulfovibrio species. Similar to vancomycin, TD-1792 showed good to moderate activity against Porphyromonas species (MIC 90 , 1 g/ ml) and Fusobacterium species (MIC 90 , 4 g/ml).
Quality control strains were tested six times against TD-1792. The result for Staphylococcus aureus (ATCC 29213) was 0.03 g/ ml, and Clostridium difficile (ATCC 700057) had a range of 0.5 to 1.0 g/ml. The comparator agents had values within their accepted ranges (6, 7) .
TD-1792 is a potent new agent active in vitro against a wide spectrum of Gram-positive anaerobes, especially more resistant species of clostridia such as C. innocuum and C. ramosum. TD-1792 was active in vitro against only some Gram-negative anaerobic bacteria, such as Porphyromonas and Fusobacterium species. It shows promise as a valuable addition to our armamentarium against pathogenic Gram-positive bacteria, yet it does not affect most Gram-negative anaerobic organisms in the intestinal microbiome. TD-1792 warrants further clinical evaluation. (2) . i Fusobacterium necrophorum (2) and F. nucleatum (8) . j Prevotella bivia (9) , P. disiens (3), P. intermedia/nigrescens group (1), P. loescheii (4), and P. melaninogenica (3) . k Porphyromonas asaccharolytica (4), P. gingivalis (2), P. somerae (4), P. levii (1) , and Porphyromonas species (1). 
